NKY: New Anjin and Weirongte are actively advancing clinical trials as planned
Finet HK
On January 22, NKY (300109.SZ) stated on the interactive platform that as of now, the company holds 11.1111% of shares in Nuoanjin and 8.1694% in Weirongte. Nuoanjin and Weirongte are actively advancing clinical trials as planned
The content of this article is for reference only and does not represent Longbridge's position, nor does it constitute any investment advice. Investment involves risks, please invest cautiously.
